EchoIQ LimitedASX: EIQ

EchoSolv HF FDA 510(k) update

· Issued by EchoIQ Limited via ASX

Filed with ASX · · 1 page · English

Summary by 6ix AI

The company has filed a request for supervisory review of the FDA's Not Substantially Equivalent determination, which has been accepted by the regulator. A meeting with the FDA related to this appeal is expected to take place soon, which will clarify the regulatory pathway for EchoSolv HF. Further updates will be provided as developments occur regarding the regulatory process.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/echosolv-hf-fda-510k-update

Release

Echo IQ Limited | ABN 48 142 901 353 Level 11, 66 Clarence St, Sydney NSW 2000, Australia +61 2 9159 3719 | www.echoiq.ai ASX: EIQ 12 October 2026 EchoSolv HF FDA 510(k) update Sydney: AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ)...

EchoIQ Limited on 6ix

Story so far

Earlier from EchoIQ

Later from EchoIQ

All EchoIQ news releases